GlassScriptPhysician profile
Matthew John Miles
NPI 1588009310
$8,161.59
in general payments reported to CMS, 2019-2025
20 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $262 · 2021: $523 · 2022: $295 · 2023: $511 · 2024: $6,203 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,689 · Travel and Lodging: $1,131 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,688.51 |
| Travel and Lodging | $1,130.91 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,141.82 | 2024 | |
| Glaxosmithkline, LLC. | $1,059.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Merck Sharp & Dohme LLC | $252.13 | 2019-2020 | |
| Medtronic, INC. | $161.85 | 2023-2024 | Illumisite |
| Ethicon INC. | $109.58 | 2021 | |
| Grifols USA, LLC | $73.01 | 2021-2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.31 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $48.12 | 2022 | |
| United Therapeutics Corporation | $44.38 | 2023-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $41.84 | 2023-2024 | Fasenra |
| Insmed, INC. | $23.56 | 2025 | Arikayce |
| Genentech USA, INC. | $20.92 | 2022 | |
| Tactile Systems Technology INC | $20.92 | 2021 | |
| Pulmonx Corporation | $19.57 | 2021 | |
| Mylan Specialty L.P. | $17.87 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $16.13 | 2022 | |
| Boston Scientific Corporation | $15.32 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.39 | 2021 | |
| Shire North American Group INC | $14.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.